Bio-Rad Laboratories, Inc. Co-Founder and Director Emeritus Alice Schwartz Passes Away

Alice N. Schwartz, co-founder and Director Emeritus of Bio-Rad Laboratories, Inc., passed away on September 25, 2025, at the age of 99. Her legacy in scientific innovation began when she co-founded Bio-Rad in 1952, shortly after earning her biochemistry degree from the University of California, Berkeley. Together with her husband, David Schwartz, she initially focused on specialty chemicals for life science research. However, their vision quickly expanded into the clinical diagnostics sector, significantly shaping the landscape of biomedical advancements.

Alice was pivotal in the development of Bio-Rad's first thyroid function test kit in the 1960s. This kit utilized separation techniques and materials refined through prior research efforts, marking an important entry into clinical diagnostics for the company. This innovation not only catalyzed Bio-Rad’s growth but also laid the groundwork for its future success in medical technology.

Throughout her tenure, Alice Schwartz exemplified dedication and leadership, remaining an active board member until 2022. Her commitment to scientific inquiry and her influence in the company fostered a culture of excellence and innovation that continues to inspire colleagues and aspiring scientists alike.

Bio-Rad Laboratories, headquartered in Hercules, California, is recognized as a global leader in life science research and clinical diagnostics. With approximately 7,500 employees and $2.6 billion in revenues for 2024, the company serves a wide array of customers, including educational institutions, hospitals, and pharmaceutical companies. Bio-Rad remains dedicated to advancing science and improving health outcomes through high-quality products. Alice Schwartz's contributions are part of an enduring legacy that will continue to influence future generations in the scientific community.

The recent passing of Alice N. Schwartz, co-founder and Director Emeritus of Bio-Rad Laboratories, Inc., marks a significant chapter in the company’s storied history. Mrs. Schwartz's legacy, particularly her contributions in pioneering clinical diagnostics, has profoundly influenced the growth trajectory of Bio-Rad, which remains a leader in life science and clinical diagnostics.

Investors in Bio-Rad (NYSE: BIO and BIO.B) may find it essential to assess the implications of this change in leadership. While the co-founder’s departure could create short-term uncertainties, it also opens an opportunity for the company to innovate and evolve under new leadership. As a publicly traded entity with approximately $2.6 billion in revenue, Bio-Rad’s strategic focus lies in expanding its product portfolio and improving operational efficiencies.

Despite the emotional impact of losing a visionary like Schwartz, Bio-Rad is well positioned in a booming sector, fueled by advancements in biotechnology and healthcare demand. The company's extensive customer base, including universities and biopharmaceutical firms, reinforces its market strength. Furthermore, increased government spending in health and research industries positions Bio-Rad favorably for innovative growth.

Investors should look for potential volatility in the short term due to the transition period. However, if the company maintains its commitment to R&D, the fundamentals suggest that Bio-Rad can continue its upward trajectory. Monitoring upcoming earnings reports and management commentary will be critical as the company navigates this transition.

In conclusion, while Alice Schwartz’s passing is a significant loss, Bio-Rad's foundational strengths and market opportunities remain intact. Investors may consider viewing any price dips as potential buying opportunities, particularly for those with a long-term investment horizon in the ever-evolving life sciences sector.